Ambetter transplant denied: how to appeal

Quick answer

If Centene / Ambetter denied your transplant and immunosuppressant, you can appeal, and the plan must give you its file and the criteria it used. Filing windows by plan type: at least 180 days (insured and Marketplace plans); 60 days from the notice (Medicaid managed care); 65 days from the notice (Medicare Advantage). The date printed on your denial notice controls; it can only be later than these floors, never earlier.

Why Centene / Ambetter denies transplant and immunosuppressant

Centene operates one of the largest Medicaid footprints in the U.S. and sells ACA marketplace coverage under the Ambetter brand. Marketplace plans drew elevated regulator and journalist scrutiny in 2024 for higher-than-average denial rates on in-network claims, and Centene-managed Medicaid lines vary plan-by-plan by state.

For transplant and immunosuppressant specifically: Solid-organ transplant patients depend on continuous immunosuppressive therapy to prevent rejection. UNOS/OPTN guidelines establish that immunosuppressant regimens generally cannot be switched without significant clinical risk. Denials of transplant evaluation, listing, surgery, or maintenance immunosuppression are among the most clinically urgent appeals.

The law that controls this appeal

UNOS/OPTN clinical guidelines govern eligibility and continuity of care; Medicare Part B covers post-transplant immunosuppressants by statute.

At a glance

Centene / Ambetter appeals: the rule, the deadline and the next level, by plan type

Which row applies depends on the plan you hold, not on Centene / Ambetter's brand. Your ID card, the Summary Plan Description and the denial letter say which.

Plan type	Rule that governs	File your appeal within	The plan must answer	If the plan says no again
Fully insured employer, individual or Marketplace plan The carrier holds the risk and is licensed in your state. Small employers and almost all individual and HealthCare.gov plans.	45 CFR 147.136 (Public Health Service Act § 2719), which applies the 29 CFR 2560.503-1 procedures and adds state external review; state insurance law on top.	At least 180 days from the denial (45 CFR 147.136(b); 29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days. Prior-authorization decisions by Marketplace issuers from 2026: 72 hours expedited, 7 calendar days standard (CMS-0057-F).	External review through your state's process, or the federal process where the state has none, generally within 4 months of the final internal denial (45 CFR 147.136(c), (d)). The state insurance department and its Consumer Assistance Program take complaints.
Medicaid managed care plan A Medicaid plan run by the carrier under a state contract. The card says Medicaid, Medi-Cal, STAR, HealthChoice or your state's programme name.	42 CFR Part 438, Subpart F (plan appeals) and 42 CFR Part 431, Subpart E (state fair hearings).	60 calendar days from the date on the notice of adverse benefit determination to request the plan's appeal (42 CFR 438.402(c)(2)(ii)). State fair hearing: within 120 calendar days of the plan's appeal decision (§ 438.408(f)(2)).	Standard appeal: 30 calendar days. Expedited: 72 hours (42 CFR 438.408(b)).	A state fair hearing after the plan's single level of appeal (§ 438.402(b)); some states add an external medical review. Benefits continue during the appeal if you ask within 10 calendar days of the notice (§ 438.420).
Medicare Advantage (Part C) A private plan that replaces Original Medicare. The card says Medicare Advantage, HMO, PPO or PFFS.	42 CFR Part 422, Subpart M (§§ 422.560 to 422.634). Coverage decisions must follow Original Medicare rules (42 CFR 422.101).	65 calendar days from the date on the denial notice to request the plan's reconsideration (42 CFR 422.582, as amended effective 1 January 2025).	Expedited: 72 hours. Standard pre-service: 30 days (7 days for Part B drugs). Payment: 60 days (42 CFR 422.590).	If the plan does not fully reverse itself it must send the case to the Independent Review Entity on its own (42 CFR 422.592); then an ALJ hearing when the amount in controversy meets the annual threshold, the Medicare Appeals Council and federal court. State external review does not apply.

Fully insured employer, individual or Marketplace plan

What you can demand. The plan must give you the claim file, the criteria it applied and any new evidence or rationale before the final decision, free of charge (45 CFR 147.136(b)(2)(ii)(C); 29 CFR 2560.503-1(h)(2)(iii)).

How to open the appeal. Cite 45 CFR 147.136 and 29 CFR 2560.503-1: request the claim file and the criteria, note the decision clocks, and name the state external-review right.

Medicaid managed care plan

What you can demand. Free copies of the case file, medical records and the criteria used, before and during the appeal (42 CFR 438.406(b)(5)). Children under 21 have EPSDT rights to medically necessary care (42 U.S.C. 1396d(r)(5)).

How to open the appeal. Cite 42 CFR 438.402 and 438.406(b)(5): request the case file and the criteria, ask for continued benefits within 10 days, and reserve the state fair hearing.

Medicare Advantage (Part C)

What you can demand. The plan may not apply internal criteria that are more restrictive than Medicare's national and local coverage determinations, and must decide medical necessity on your individual circumstances (42 CFR 422.101(b), (c)). You can ask for the case file and the criteria used.

How to open the appeal. Cite 42 CFR 422.582 and 422.101(c): the plan must decide on your individual circumstances under Medicare coverage rules, and must forward an unfavorable reconsideration to the IRE itself.

Reported denial rates

In the CMS Transparency in Coverage data for plan year 2026 (2024 claims), the 27 Centene / Ambetter-family Marketplace issuer filings across 21 states reported in-network claim denial rates from 13.7% to 36.3% (median 18.8%). Issuer-level, self-reported, HealthCare.gov plans only; a denial includes duplicate and administrative denials.

Centene / Ambetter denial rate: every state, three years →

Primary sources for this table

Windows are federal floors or the rule as written; the denial notice controls. Reviewed 13 September 2026. General information, not legal advice; Apellica is not a law firm.

What Centene / Ambetter denies for transplant and immunosuppressant

The transplant and immunosuppressant services most often denied:

Transplant evaluation and waitlisting
Transplant surgery (kidney, liver, heart, lung)
Specific brand of immunosuppressant (tacrolimus, mycophenolate, sirolimus)
Generic-to-brand switches denied
Anti-rejection biologic therapy
Out-of-network transplant centers

Why transplant and immunosuppressant claims get denied

A typical Centene / Ambetter transplant and immunosuppressant denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Plan claims patient not medically eligible for transplant
Step therapy on immunosuppressants
Plan formulary forces switch from brand to generic
Out-of-network transplant facility
Post-transplant complications denied as unrelated

The Centene / Ambetter appeal process

Appeal levels: Marketplace: internal appeal then federal external review (IRO). Medicaid: plan appeal then state fair hearing. Medicare Advantage: federal 5-level ladder.

Carrier timing: 180 days from denial for marketplace internal appeals; 4 months / 120 days for federal external review. Medicaid fair-hearing deadlines vary by state, often as short as 90-120 days.

Transplant timing: Urgent appeals: 72 hours. Standard: 30 days for prior auth, 60-180 days filing window. Transplant cases routinely qualify for expedited urgent review.

What we know about Centene / Ambetter: We confirm the specific Centene subsidiary (Ambetter, Sunshine Health, Wellcare, etc.) before filing, because procedural rules and the supervising regulator change with the line of business.

Common Centene / Ambetter denial patterns for transplant and immunosuppressant

ACA marketplace in-network denials. Ambetter marketplace plans have been documented denying in-network medical claims at rates above the marketplace average. Federal ACA rules guarantee internal appeal plus external review via an Independent Review Organization (IRO), both are no-cost to the member.
Narrow networks driving care-access denials. Ambetter HMO products often run narrower networks than the local competition. Network-adequacy challenges (state DOI complaints citing inadequate specialist access) can convert an out-of-network denial into in-network coverage.
Medicaid managed care fair hearings. Centene-managed Medicaid plans (Sunshine Health, Buckeye, Peach State, etc.) operate under each state's Medicaid rules. After plan-level appeal, members have the right to a state fair hearing, a binding administrative process with strong reversal history.

How to win your Centene / Ambetter transplant and immunosuppressant appeal

Strategy for transplant and immunosuppressant: Cite UNOS/OPTN clinical guidelines for transplant eligibility and continuity of care. For immunosuppressant switch denials, attach the treating transplant team's letter documenting the rejection risk from any regimen change. Many plans have specific transplant carve-out networks (Centers of Excellence), confirm in-network status of the specific center before assuming OON. Medicare Part B covers immunosuppressants post-transplant under federal law.

Filed against Centene / Ambetter, that strategy rides on this procedural spine:

Procedural-rights anchor. Cite 45 CFR 147.136 and 29 CFR 2560.503-1: request the claim file and the criteria, note the decision clocks, and name the state external-review right. If your Centene / Ambetter coverage is a different plan type (Medicaid managed care plan, Medicare Advantage), use that row of the table above instead; the rule and the deadline change with the plan, not the carrier.
Criteria-disclosure demand. Centene / Ambetter frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. UNOS/OPTN clinical guidelines govern eligibility and continuity of care; Medicare Part B covers post-transplant immunosuppressants by statute.
Treating-provider attestation. A letter from the treating physician addressing each criterion in Centene / Ambetter's own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the transplant and immunosuppressant denial and approve the service, not a general "please reconsider."

Documents you'll need for your Centene / Ambetter transplant and immunosuppressant appeal

Denial letter
Transplant team's letter and treatment plan
UNOS / center listing documentation
Lab values supporting transplant indication
Prior immunosuppressant trial history (if relevant)

What a transplant and immunosuppressant appeal can recover

Typical recovery for transplant and immunosuppressant cases runs $10,000 - $1,000,000+. The exact figure depends on the specific service and your plan's contracted rates.

Centene / Ambetter transplant and immunosuppressant appeals: frequently asked questions

Can I appeal your Centene / Ambetter transplant or immunosuppressant denial?

Yes, and these are among the most clinically urgent appeals. Cite UNOS/OPTN clinical guidelines for eligibility and continuity of care, and request expedited 72-hour review where rejection risk is in play.

Can Centene / Ambetter force me to switch immunosuppressants?

You can contest it. UNOS/OPTN guidance is that immunosuppressant regimens generally cannot be switched without significant rejection risk; attach your transplant team's letter documenting that risk for any forced brand-to-generic or formulary switch.

Is my transplant center in network?

Many plans use specific transplant Centers of Excellence networks. Confirm the center's status before assuming it is out of network, because a carve-out network often covers a center that the general directory does not list.

Are post-transplant drugs covered by Medicare?

Yes. Medicare Part B covers immunosuppressive drugs following a covered transplant by federal law, which is a direct counter to a maintenance-immunosuppression denial.

What Apellica does for Centene / Ambetter transplant and immunosuppressant appeals

We file appeals against Centene / Ambetter specifically configured to its internal review process. Every transplant and immunosuppressant appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Centene / Ambetter appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your Centene / Ambetter transplant and immunosuppressant appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

Centene / Ambetter denied your transplant and immunosuppressant? Here is what to do next